A Retrospective Analysis of the Impact of Adverse Event-Triggered Idelalisib Interruption and Dose Reduction on Clinical Outcomes in Patients with Relapsed/Refractory B-Cell Malignancies

Publication date: Available online 24 December 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Shuo Ma, Rebecca J. Chan, Lin Gu, Guan Xing, Nishanthan Rajakumaraswamy, Bianca B. Ruzicka, Nina D. Wagner-Johnston
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research